1. Home
  2. LPRO vs ALT Comparison

LPRO vs ALT Comparison

Compare LPRO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPRO
  • ALT
  • Stock Information
  • Founded
  • LPRO 2000
  • ALT 1997
  • Country
  • LPRO United States
  • ALT United States
  • Employees
  • LPRO N/A
  • ALT N/A
  • Industry
  • LPRO Finance: Consumer Services
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • LPRO Finance
  • ALT Health Care
  • Exchange
  • LPRO Nasdaq
  • ALT Nasdaq
  • Market Cap
  • LPRO 252.9M
  • ALT 292.0M
  • IPO Year
  • LPRO N/A
  • ALT N/A
  • Fundamental
  • Price
  • LPRO $2.26
  • ALT $3.78
  • Analyst Decision
  • LPRO Buy
  • ALT Strong Buy
  • Analyst Count
  • LPRO 6
  • ALT 6
  • Target Price
  • LPRO $3.00
  • ALT $17.40
  • AVG Volume (30 Days)
  • LPRO 636.8K
  • ALT 3.0M
  • Earning Date
  • LPRO 11-06-2025
  • ALT 08-12-2025
  • Dividend Yield
  • LPRO N/A
  • ALT N/A
  • EPS Growth
  • LPRO N/A
  • ALT N/A
  • EPS
  • LPRO N/A
  • ALT N/A
  • Revenue
  • LPRO $16,254,999.00
  • ALT $20,000.00
  • Revenue This Year
  • LPRO $311.24
  • ALT N/A
  • Revenue Next Year
  • LPRO $13.17
  • ALT $761,880.20
  • P/E Ratio
  • LPRO N/A
  • ALT N/A
  • Revenue Growth
  • LPRO N/A
  • ALT N/A
  • 52 Week Low
  • LPRO $0.70
  • ALT $2.90
  • 52 Week High
  • LPRO $6.92
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • LPRO 55.53
  • ALT 50.81
  • Support Level
  • LPRO $2.01
  • ALT $3.54
  • Resistance Level
  • LPRO $2.34
  • ALT $3.84
  • Average True Range (ATR)
  • LPRO 0.13
  • ALT 0.18
  • MACD
  • LPRO 0.03
  • ALT 0.06
  • Stochastic Oscillator
  • LPRO 78.67
  • ALT 85.15

About LPRO Open Lending Corporation

Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: